Ulocladium Mold Allergy: The Alternaria Relative Hidden in Water Damage

Taxonomically, yes for the most clinically relevant species. Multiple DNA-based phylogenetic studies have reclassified Ulocladium chartarum as Alternaria chartarum, placing it directly within the Alternaria genus. Its major allergen Ulo c 1 is the ortholog of Alt a 1 — the world's most potent mold allergen — with 89% amino acid sequence identity, producing confirmed IgE cross-reactivity. Morphologically, Ulocladium and Alternaria are distinguished by conidia shape: Ulocladium produces roughly spherical 9 to 12 micrometer conidia with narrower bases, compared to Alternaria's club-shaped multicellular conidia. Ecologically, Ulocladium is primarily indoor (water-damage buildings) while Alternaria is primarily outdoor. The clinical consequence of the reclassification: Ulocladium allergy functionally overlaps with Alternaria allergy, and Alternaria immunotherapy may provide cross-protective benefit.

This is the counterintuitive finding from Moreno et al. (2016): mold-allergic patients recognized more distinct antigens from U. chartarum than from A. alternata in immunoblot studies, and showed stronger IgE reactivity to Ulocladium despite Alternaria being far more studied and commonly found in outdoor air. The explanation involves the breadth of allergen repertoire: Ulocladium may present a slightly different antigen surface than Alternaria despite the 89% shared Ulo c 1 identity, with additional IgE-binding proteins (Ulo c 2 and Ulo c 6, reactive in 40 to 58% of mold-allergic patients) that expand the sensitization profile. This finding has important clinical implications: patients in water-damaged buildings may be primarily sensitized to Ulocladium rather than outdoor Alternaria, and standard testing attributing all mold sensitization to Alternaria may miss the indoor building source.

This is biologically plausible but not formally validated in clinical trials. The 89% Ulo c 1/Alt a 1 sequence identity means that IgE tolerance induced against Alt a 1 by Alternaria immunotherapy would logically extend to Ulo c 1 cross-reactive epitopes. The reverse cross-reactivity is already established: mold-allergic patients with Alternaria sensitization show stronger IgE binding to Ulocladium than to Alternaria itself. If T-regulatory cells and blocking IgG4 antibodies are induced against the shared epitope by Alternaria SCIT or SLIT, cross-protective benefit for Ulocladium exposure is mechanistically plausible. This makes Alternaria the rational immunotherapy choice for patients with both Alternaria and Ulocladium sensitization — which most cross-reactive patients will have. Discuss this specifically with your allergist when reviewing immunotherapy options.

Yes — ImmunoCAP m204 (Ulocladium botrytis) is commercially available for specific IgE testing, and U. botrytis is included in SPT panels at some allergy practices. However, Ulocladium is not universally included in routine mold screening panels; many clinicians test only for Alternaria, Aspergillus, Cladosporium, and Penicillium. If you have a perennial indoor-worse mold allergy symptom pattern in a building with moisture history, specifically request Ulocladium testing alongside the standard panel. The finding of positive Ulocladium IgE alongside Alternaria IgE in a patient from a water-damaged building changes the clinical picture: outdoor Alternaria avoidance advice alone is insufficient; the building moisture source requires evaluation and correction.

Ulocladium is classified as a water-damage indicator mold — alongside Stachybotrys, Chaetomium, and Trichoderma — because it requires consistently elevated moisture (high water activity) to establish and grow indoors. Unlike Cladosporium or Penicillium, which can grow in moderately damp conditions, Ulocladium in significant indoor concentrations signals a structural moisture problem. Its substrate preference — gypsum board, paper, textiles, and painted surfaces — corresponds to the materials most commonly affected by water intrusion from leaking roofs, pipe leaks, or flood damage. Finding Ulocladium in a building environmental assessment therefore carries the same clinical significance as finding Stachybotrys: it triggers a search for the structural moisture source, not just surface mold removal.

The primary diagnostic difference is the exposure pattern and testing interpretation. Alternaria allergy typically presents as seasonal rhinitis and asthma worst in July to September corresponding to outdoor spore peaks. Ulocladium allergy presents as perennial rhinitis with indoor-worse patterns regardless of season. Both will typically show positive results on Alternaria whole-extract and Ulocladium m204 testing due to cross-reactivity. The environmental context is the key differentiator: a patient with perennial indoor-worse symptoms in a building with moisture history needs building assessment alongside allergy testing. Component testing with rAlt a 1 confirms the shared-epitope sensitization relevant to both genera. A negative rAlt a 1 with positive whole-Alternaria extract would suggest pan-fungal cross-reactive sensitization rather than primary Alternaria or Ulocladium sensitization.

IgE-mediated Ulocladium allergy primarily causes respiratory symptoms — rhinitis, conjunctivitis, asthma — given the inhalation exposure route. Skin manifestations (urticaria, eczema flares) from Ulocladium IgE sensitization are theoretically possible through the systemic IgE-histamine mechanism but are not well documented in published clinical literature specific to Ulocladium. More clinically relevant is the documented rare occurrence of cutaneous Ulocladium infections in immunocompromised patients — phaeohyphomycosis from Ulocladium (the mold physically invading skin tissue) — which is distinct from IgE-mediated skin allergy. Immunocompetent patients with standard mold allergy should not conflate these two separate phenomena.

Mold identification by appearance alone is unreliable — many dark-pigmented molds look similar visually, and definitive genus identification requires laboratory microscopy or PCR testing of a surface sample. If you find dark mold growth in your home, the recommended response is the same regardless of suspected genus: contact a professional mold assessor for surface sampling and laboratory identification, identify and correct the underlying moisture source, and have contaminated porous materials (drywall, carpet, ceiling tiles) professionally removed. The EPA guideline is professional remediation for areas greater than 10 square feet. For health evaluation, see a board-certified allergist who can test for Ulocladium alongside the full mold panel.

No current blood test can definitively distinguish primary Ulocladium sensitization from primary Alternaria sensitization in a patient with both, because the 89% Ulo c 1/Alt a 1 sequence identity means IgE generated against either allergen will cross-react with the other. Component-resolved testing with rAlt a 1 tests the shared epitope but cannot reveal which mold initiated the sensitization. The most informative approach combines blood testing (ImmunoCAP m204 for Ulocladium, m6 for Alternaria, m229 for rAlt a 1) with environmental assessment of the patient's specific home and work environments. If significant Ulocladium is confirmed in the indoor environment but minimal outdoor Alternaria exposure history exists, the building source is more likely to be the primary sensitizer despite the genetic relatedness of the two allergens.